TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Price, Quote, News and Summary
NYSE:TEVA - New York Stock Exchange, Inc. - US8816242098 - ADR
TEVA Quote and Key Statistics
TEVA PHARMACEUTICAL-SP ADR
NYSE:TEVA (1/17/2025, 8:04:00 PM)
After market: 21.89 -0.03 (-0.14%)21.92
+0.24 (+1.11%)
TEVA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.15% | ||
| ROE | -7.49% | ||
| Debt/Equity | 2.61 |
TEVA Performance and Technical Analysis
TEVA Ownership and Analysts
TEVA Latest News and Analysis
Teva Challenges Drug Price Law's Impact On Innovation, Generics
Teva Pharmaceuticals challenges the Inflation Reduction Act, arguing CMS's drug pricing policies harm generics, biosimilars, and innovation, disrupting healthcare balance.
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.
Teva annonce un partenariat en vue de commercialiser le candidat biosimilaire de Formycon à Eylea® (aflibercept) dans la majeure partie de l’Europe et en Israël
Klinge Biopharma GmbH (Klinge) détient les droits exclusifs de la commercialisation mondiale de FYB203, le candidat biosimilaire de Formycon, à ...
Teva gibt Zusammenarbeit zur Vermarktung des Formycon Biosimilar-Kandidaten für Eylea® (Aflibercept) in großen Teilen Europas und in Israel bekannt
Klinge Biopharma GmbH (Klinge) besitzt die exklusiven weltweiten Vermarktungsrechte für FYB203, Formycons Biosimilar-Kandidat für Eylea®1Die Vereinbarung...
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1Agreement builds...
About TEVA
Company Profile
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. The firm operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Company Info
TEVA PHARMACEUTICAL-SP ADR
124 Dvora Hanevi'a St.
TEL AVIV-YAFO 49131 IL
CEO: Kare Schultz
Employees: 35001
Company Website: https://www.tevapharm.com/
Investor Relations: https://ir.tevapharm.com/
Phone: 97239148213
TEVA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 71.36 | 688.94B | ||
| JNJ | JOHNSON & JOHNSON | 14.36 | 353.99B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.86 | 349.49B | ||
| MRK | MERCK & CO. INC. | 16.46 | 247.70B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.48 | 206.53B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.07 | 194.99B | ||
| PFE | PFIZER INC | 10.19 | 149.04B | ||
| SNY | SANOFI-ADR | 12.32 | 127.21B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.11 | 114.17B | ||
| ZTS | ZOETIS INC | 28.8 | 74.84B | ||
| GSK | GSK PLC-SPON ADR | 8.21 | 68.21B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.53 | 40.96B |